Form 6-K ALTERITY THERAPEUTICS For: Oct 31

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2026

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1	Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

 

Date: October 5, 2026

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• How Fast Will Charging Be in the Future? 2026 OMODA & JAECOO International User Summit to Unlock Next-Gen Smart Energy Experience
• SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
• Dogecoin News: DOGE Gains 3.9% After Bitwise Shuts Its ETF, Yet Pepeto Eyes a Pepe Repeat